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Abstract 
Background: More than 50% of patients with severe mental illness carry undiagnosed 
Metabolic Syndrome (MetS) comorbidities of hypertension, hyperlipidemia, or diabetes.  These 
patients are three times more likely to die of cardiovascular-related causes; however, this 
population is not routinely assessed for MetS and frequently lack appropriate treatment. 
Objective: The objective is to implement a screening tool to designed to identify risk for MetS 
and trigger appropriate treatment. 
Design: The screening tool triggers the provider to address positive criteria through interventions 
such as further evaluation, medical and/or diabetes educator consultations. 
Results: Although overall rates of screening improved significantly, follow-up interventions 
were inconsistently addressed by the providers. 
Conclusion:  Life expectancy of psychiatric patients is 25 years less than their non-psychiatric 
counterparts and although there are many factors that contribute to this incongruity, consistent 
screening and appropriate treatment of MetS may turn the tide in leveling the playing field. 
 
Keywords:  metabolic syndrome, cardio-metabolic syndrome, psychiatric, mental health 
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Metabolic Syndrome Screening Among Inpatient Psychiatric Patients 
Severe mental illness often overshadows other medical diagnoses and literature indicates 
more than 50% of patients with severe mental illness carry undiagnosed metabolic syndrome 
comorbidities such as hypertension, hyperlipidemia, and diabetes (Correll, et al., 2017).  These 
patients are three times more likely to die of cardiovascular-related causes; however, this 
population is not routinely assessed for metabolic syndrome and furthermore, patients with 
known hypertension, hyperlipidemia, and diabetes in this population frequently lack appropriate 
treatment.  Missed or untreated metabolic syndrome diagnoses are associated with increased 
length of stay, mortality during hospitalization, and 30-day all-cause readmission rates (Castillo, 
Rosati, Williams, Pessin, & Lindy, 2015).   
The project is predicated on the absence of current screening to identify metabolic 
syndrome in this high-risk inpatient psychiatric population at a university medical center.  To 
validate the impact of this deficiency, a patient list was derived from the project site’s electronic 
medical record (EMR) from the target adult inpatient psychiatric unit over a two-month period 
prior to intervention.  Fifty-eight patient charts were audited for the presence of lipid levels, 
blood pressure values, and fasting blood glucose levels.  Waist circumference measurements are 
currently not a standard procedure so no values were present for this measurement in pre-data.  
Additionally, diagnosis lists were audited for presence of pre-existing metabolic syndrome 
diagnoses and the medication administration record (MAR) was audited for corresponding 
presence of treatment.  Although the presence of most antipsychotic and mood stabilization 
medications poses greater risk for metabolic syndrome, screening was designed to target all new 
admissions regardless of medication treatment, opting for standardization versus specificity.   
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Of all the risk indicators, blood pressure was the only consistent measurement for all 
patients at the project site.  Blood draws for basic metabolic panels (BMP) were fairly routine so 
fasting blood glucoses were also highly prevalent though lipid panels were rare despite the lipid 
panel’s ability to be tested on the same blood tube as the BMP.  Evaluation of the presence of 
predictive values in conjunction with corresponding diagnoses and treatments yielded 
noteworthy results.  Pre-data indicates a significant deficiency in diagnosis and treatment of 
suspected hypertension, hyperlipidemia, and diabetes. 
Literature Review 
Evidence presented are the results of searches in PubMed, CINAHL Complete, ProQuest 
Health & Medicine, PsycARTICLES, and PsycINFO using the MeSH terms metabolic 
syndrome, cardiometabolic syndrome, antipsychotics, psychiatric, and mental health.  Literature 
is presented based on the hierarchy of evidence where Level I is the strongest evidence and Level 
VII the weakest (O'Mathuna & Fineout-Overholt, 2015). 
 Bai, et al. (2016) performed a quasi-experiment with 143 patients treated with atypical 
antipsychotics plus mood stabilizers and atypical antipsychotic monotherapy.  These patients 
were evaluated for the prevalence of metabolic syndrome and found dual therapy led to 
significantly more adverse patient outcomes in number of hospitalizations, number of psychotic 
episodes, severity in side effects such as tardive dyskinesia, and global functioning in the 
presence of metabolic syndrome compared to those with dual therapy without metabolic 
syndrome.  This is a Level III evidence due to its well-designed quasi-experiment without 
randomization however due to its cross-sectional design, direct correlation is unclear so causal 
relationship remains in question.  Despite this flaw, results do indicate a need for integrated 
collaborative care for this complex patient type. 
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 Correll, et al. (2017) performed a retrospective data analysis that further supported the 
above findings by concluding those with bipolar disorder, more frequently treated with dual 
therapy, had more negative outcomes than those with schizophrenia, which is usually treated 
with monotherapy in the presence of metabolic syndrome (Level IV).  These negative outcomes 
were significant in 30-day readmission rates, longer lengths of stay, and mortality.  This was an 
exceptionally large study sample of 57,506 patients with schizophrenia and 124,803 patients with 
bipolar disorder.  This study indicated progressively worse outcomes based on the number of 
metabolic comorbidities present.  This retrospective study also provided financial impact based 
on 2014 dollars.  Average costs for a patient treated for schizophrenia or bipolar disorder without 
metabolic syndrome was $7126 - $10,606 however with every one metabolic comorbidity 
present, an additional $2000-3000 cost was incurred.  Among this sample, over 60% had at least 
one metabolic comorbidity.  Another study supported this outcome and found among 67 patients 
with bipolar disorder, 53.7% had co-occurring metabolic syndrome (Kumar, et al., 2017) while 
Castillo, Rosati, Williams, Pessin, & Lindy (2015) found a 52% prevalence among 10,084 
psychiatric outpatients with varying diagnoses. 
 Although most literature available indicates antipsychotics are the primary culprits of 
increasing metabolic syndrome risk, Kahl, et al. (2017) found that patients with Major 
Depressive Disorder (MDD) primarily treated with selective serotonin reuptake inhibitors were 
four times more likely to develop pericardial adipose tissue, which increases prevalence of 
coronary artery disease (Level IV).  Fifty patients were included and split between MDD less 
than two years and MDD greater than two years.  A control group of 25 participants were 
recruited without any psychiatric disorders.  Extensive measurements were collected to account 
for confounding factors and interestingly, smoking was not a statistically significant impact.  
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Physical activity, severity of the Beck Depression Inventory, cortisol levels, and tumor necrosis 
factor-a were statistically significant.  Although there were four patients who received an 
antipsychotic or mood stabilizer for the treatment of their depression, the majority of the patients 
received a serotonin reuptake inhibitor or some kind.  This study supports metabolic syndrome 
screening for all psychiatric population, not just for those prescribed antipsychotics or mood 
stabilizers. 
 While there is a plethora of evidence indicating the value of metablic syndrome 
screening, very little was found in the resulting indicated treatments provided and its effects on 
patient outcomes, which indicates a need for more definitive outcome research for this 
disadvantaged population. 
Framework 
The framework for this evidence-based project is the Iowa model.  This model is practice-
oriented with a focus on improving health outcomes by providing simplistic guidance on 
evidence use specifically to the practitioner in the acute care setting (Dang, et al., 2015).  The 
question of metabolic syndrome screening and its impact on the inpatient psychiatric population 
is an acute problem-based question where the practitioner can take direct action.  The Iowa 
model essentially starts with a problem or question (trigger) and builds the step-by-step process 
in a decision-tree algorithm.  The model poses three major questions and offers correlating 
actions based on the nature of the answers assessed.  The first question establishes a shared 
priority between the implementer and the organization.  The second question establishes 
adequate evidence in literature for the project.  Within this segment of the model, the pilot 
practice change is implemented based on evidence found. The model provides components of the 
pilot practice change to include outcome selection, baseline data collection, development of 
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project guidelines, implementation on the designated unit, evaluation of the process and 
outcomes, and modifications of the guideline based on the evaluation.  The third question 
determines success or failure.  If successful, the model continues to the house-wide practice 
change implementation, monitoring process, and dissemination process.  This decision point 
format allows pertinent questions to drive the project in the appropriate direction and provides a 
simplistic step-by-step list of actions for each point (Dang, et al., 2015). 
Successful implementation of this project is reliant on consistent and persistent education 
and reinforcement of staff performance.  Bandura’s Theory of Self Efficacy consists of four 
elements: successful performance, vicarious experience, verbal persuasion, and emotional 
arousal (McLeod, 2011).  In successful performance, the clinician must experience success in 
order to develop self-efficacy.  In vicarious experience, the clinician can experience success 
through modeled behavior.  In verbal persuasion, the clinician receives encouragement and praise 
from the coach, peers, or trainer.  In emotional arousal, consistent support of the first three 
elements will continue to support readiness to learn (McLeod, 2011).  Extensive education on 
use of the screening tool as well as this learning theory was taught to primary staff trainers 
referred as super-users of the target unit.  These super-users were trained to model the procedure 
as well as coach each staff person through the process until proper procedure was demonstrated.   
Purpose 
Metabolic syndrome criteria require measurements of waist circumference, serum lipid levels, 
blood pressure, and fasting blood glucose (National Institute of Health, 2016).  This project 
implements a screening tool primarily designed to identify patients at high risk for metabolic 
syndrome and trigger treatment of positive indicators of hypertension, hyperlipidemia, and 
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diabetes.  A secondary goal is to focus attention to patients with pre-existing metabolic syndrome 
diagnoses who are not currently receiving treatment. 
Methods 
The project design encompassed direct-care staff and physician education, utilization of a 
screening tool, completion of all measurements indicated by the tool, and treatment response 
based on positive criteria.  Education focused on metabolic syndrome and its impact on the 
inpatient psychiatric population, specifically its physiologic impact and overall impact on patient 
outcomes.  In addition, physicians were educated on the suggested treatment goals based on 
National Institute of Health’s (NIH) recommendations (U.S. Department of Health and Human 
Services, 2001). 
The applied setting is a university teaching hospital with multiple psychiatric units 
primarily staffed by medical residents rotating through different units every three to six weeks.  
This model presented challenges with training, making frequent training sessions vital to the 
project’s success.  The diagnoses of the target unit are diverse, encompassing primarily 
depressive and anxiety disorders with suicidal or psychotic features, bipolar disorders, and 
various psychotic disorders and although the presence of antipsychotics is generally accepted as 
higher risk for metabolic syndrome, as Kahl et al. (2017) indicated, depressive disorders may 
have a strong correlation with metabolic syndrome as well.  The screening tool was implemented 
for all new admissions regardless of diagnosis to incur consistency in practice and performance 
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Interventions 
The screening tool was developed (see Appendix) using NIH criteria and treatment options to 
provide a one-page tool for both direct-care staff and physicians to facilitate ease of use 
(National Institute of Health, 2016).  The tool was designed as a checkbox system for quick 
response in the assessment process.  Education sessions were offered twice weekly for one 
month prior to implementation regarding the evidence for screening and the screening process 
itself.  The target audiences included direct care nursing and psychiatric tech staff and provider 
staff during beginning-of-shift huddles for direct care staff and case conceptualization huddles 
for provider staff.  Upon implementation of the screening tool, staff were instructed to page this 
writer to provide assistance and support during the admission and screening process. 
Monitoring. A primary process indicator was monitoring, guidance, and facilitation three 
days per week during the two-month intervention phase to ensure appropriate utilization.  A 
second process indicator was weekly monitoring and chart audits for completion of 
measurements for each patient within 36 hours after admission and appropriate completion of the 
screening tool.  This indicator also monitored for treatment follow-up based on completed 
screens.  This is a crucial indicator due to the prevalence of diagnoses without treatment 
(Castillo, Rosati, Williams, Pessin, & Lindy, 2015). 
Measures. Current practice does not actively identify patients at high risk for metabolic 
syndrome so project outcome indicators included screening for metabolic syndrome risk criteria 
for 80% of admitted patients and treatment initiation of 50% of positively screened patients.  A 
second outcome indicator is the identification of patients with current diagnoses of metabolic 
syndrome without current appropriate treatment, which is a discrepancy Zimmerman & Maher 
(2013) highlights.  A third outcome indicator is the delivery of treatment associated with newly 
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found conditions implicated by the screening tool.  Treatment of these conditions lead us to 
expected long-term outcomes such as decreased length of stay, mortality during hospitalization, 
and 30-day all-cause readmission rates.  Because metabolic anomalies are not often resolved or 
managed in the acute phase of care, expected long-term outcomes require at least six months to 
one year to determine effect of risk identification and treatment (Barnes, Bhatti, Adroer R, & 
Paton, 2015). 
Each patient record with a completed screen was evaluated for confirmation of 
appropriate screening and provision of any missing screening data as well as treatments 
continued or initiated during the hospital stay.  As every patient was subject to screening, there 
were little ethical concerns related to withholding of assessment or treatment. 
Results 
For pre-intervention comparison, a list of patients admitted during a two-month period 
prior to intervention elicited 58 patients.  Each patient record was evaluated for results of lipid 
panel, blood pressure, fasting blood glucose, admitting diagnoses, newly recorded diagnoses 
during their current stay, and treatments continued or initiated during their stay.  The total 
number of eligible patients during the intervention months was 43 and although 17 screens were 
lost during the intervention process, a total of 38 screens were at least partially performed, 
indicating 88% completion of screens for all new admissions, surpassing the 80% completion 
goal.  Of the 21 collected screens, increases in completion percentages were significant across 
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Table 1 
Percentage of Measurements Completed During Pre-Intervention and Intervention 
  Lipid Panel BP FBG waist  
PRE: Adult IP Psych Unit 
(n=58) 30% 100% 82% 0% 
INT: Adult IP Psych Unit 
(n=21) 71% 100% 100% 38% 
Note: BP is blood pressure; FBG is fasting blood glucose; waist is waist 
circumference. 
Furthermore, 33% - 62% were screened to be at positive risk for metabolic syndrome compared 
to 21% in the pre-data collection.  The range of percentage is attributed to the missing criteria 
that may or may not indicate a positive screen.  For evaluation purposes, missing waist 
circumference data with a body mass index ³ 25 was accepted as a positive criterion. 
Table 2 
Results of Risk Criteria Screens 
  NO RISK UTA 
POSITIVE 
RISK 
0 Risk Criteria 3 1 0 
1 Risk Criteria 2 2 0 
2 Risk Criteria 3 3 0 
3 Risk Criteria 0 0 3 
4 Risk Criteria 0 0 3 
5 Risk Criteria 0 0 1 
# Criteria Missing 3 10 3 
BMI ≥ 25 2 4 3 
Note:  Assumptions: 1. BMI ³25= POSITIVE criteria for waist circumference; 2. UTA = based 
on pre-existing and missing criteria, it is possible that either positive or negative result may 
occur. 
 
Another measure evaluated was the identification of metabolic syndrome diagnoses and its 
subsequent addition to the problem list.  Among hyperlipidemia, hypertension, and diabetes, 
hyperlipidemia was the most significantly increased from the pre-data collection.  Hypertension 
also increased almost two-fold compared to pre-data collection as well.  The identification of 
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diabetes has challenges inherent to the disease in that it requires multiple abnormal fasting blood 
glucoses and measurements of HgbA1c to confirm the diagnosis.  Because the fasting blood 
glucose measurement is often singular in a typical admission, it is not surprising that the 
identification of diabetes is not significant.  In both diagnosis identification and treatment 
delivery, diabetes does not appear to have any significant impact in context of this project. 
Table 3 





was the presence of treatment based on a positive screen for the indicated comorbidity.  With the 
exception of diabetes, both hyperlipidemia and hypertension treatment increased significantly.  
Treatments for hyperlipidemia and hypertension include anti-hyperlipidemia or antihypertensive 
medications as well as instructions for lifestyle modifications in activity and/or diet attributed 
specifically to address hyperlipidemia or hypertension in the problem list.  Treatments for 
diabetes include oral or subcutaneous anti-hyperglycemic medications, instructions for lifestyle 
modifications in activity and/or diet attributed specifically to address diabetes in the problem list, 
or diabetes educator consultation during hospitalization. 
Table 4 
Prevalence of Treatment Based on Positive Screening Criteria 
 
  PRE-DATA: Corresponding Dx (n=58) 
INTERVENTION: 
Corresponding Dx (n=21) 
Hyperlipidemia 11% 50% 
Hypertension 41% 75% 
Diabetes 68% 30% 
  PRE-DATA: Corresponding Tx (n=58) 
INTERVENTION: 
Corresponding Tx (n=21) 
Hyperlipidemia 28% 63% 
Hypertension 63% 92% 
Diabetes 61% 60% 
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This project had multiple challenges to overcome in virtually every step of the project 
progression.  The organization was in the midst of transitioning from one electronic medical 
record system to another so paper screening tools were used for nursing staff to complete at the 
time of admission.  Individual screening tools had distinct identifiers to de-identify data and 
allow for unbiased review of information, however, despite instructions to notify this writer for 
additional screening tools, staff photocopied the tool so there were multiple completed screens 
with the same identifier.  Multiple tape measures were provided to staff to ensure waist 
circumference was measured upon admission, however, loss of the tape measures was a constant 
challenge despite its single location on the unit.  Because of the frequent inability to measure 
waist circumference, “eye balling” was encouraged about three weeks into the project with an in-
service with visual aids to assist in improving accuracy.  The admission process can be a chaotic 
time in context of the patient being acutely distressed.  The act of physically measuring waist 
circumference was often challenging as well so “eye balling” was frequently the only avenue of 
assessment.  Another challenge was the completion of the screening tool itself.  Because the 
information required to indicate risk was often in the electronic medical record, nursing staff did 
not always pursue the information immediately, rather waiting up to 48 hours post admission if at 
all, so many completed screens were partial assessments of risk.  Communication between 
nursing staff and providers was also inconsistent and was often met with delayed or assigned low 
priority leading to poor follow-up.  Despite these challenges, virtually every new admission was 
at least partially screened, however 17 completed screens were lost during the intervention 
process thus losing about half the intervention data, making the intervention sample 21 versus 
43. 
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Discussion 
There is extensive evidence that screening for metabolic syndrome is essential to address 
the high rate of complications for the psychiatric population.  With the exception of diabetes, 
screening for the presence and detection of hyperlipidemia and hypertension was followed by 
increased occurrences of corresponding additions to the problem list and treatments.  The 
intervention phase had its challenges, specifically the loss of more than half the patients actually 
screened, and because the screens were unavailable for review, there was no way to determine 
the extent of the screen completion.  Anecdotally, staff reported increased awareness of 
metabolic syndrome and its impact on their patients and often recalled times where they 
encouraged more outdoor activities or sought out diabetes educators for their patients if the 
opportunity and ability arose.  This quasi-Hawthorne effect may partially account for the 
increased treatment delivery despite multiple incomplete screenings.  As mentioned earlier, 
diabetes screening continued to be a challenge since the majority of patients received a single 
fasting blood glucose evaluation and many who had single abnormal initial fasting glucose levels 
did not have follow-up assessments done. 
Screening produced a range of 33%-62% of patients with positive risk for metabolic 
syndrome, which aligns with Bai, et al’s (2016) finding that more than 50% of psychiatric 
patients have metabolic syndrome comorbidities.  Long term evaluation would be necessary to 
determine the screening’s effects on length of stay, readmission rates, and mortality.   
 Lability in today’s health care market makes it difficult to assess true cost of multi-
system conditions such as metabolic syndrome.  According to Zimmerman and Mehr (2013), 
metabolic syndrome increases average cost of healthcare by 60% per year, however, that does 
not take into account the additional financial impact of concurrent psychiatric diagnoses.  The 
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average non-psychiatric patient will have an increased cost of $1860 per year but for each 
additional positive criteria of metabolic syndrome, costs increase by 24% (Zimmerman & Mehr, 
2013).  For the psychiatric population, Correll, et al. (2017) posits every singular metabolic 
comorbidity present incurs an additional $2000-$3000 per year indicating an average patient 
with bipolar disorder with three comorbidities could incur a $19,606 hospital bill per annum, 
nearly doubling the cost of managing bipolar disorder alone.  Initial cost of project 
implementation was minimal; however, additional time was spent by the direct-care staff to take 
additional measurements indicated by the screening tool.  The tool was designed for ease of use 
but may potentially take no longer than 30 minutes for measurements and completion of the tool 
questions.  The average RN pay is $50/hour so each encounter would cost $25 per patient.  
Subsequent treatments indicated by the screening tool may vary but daily medication 
management is a requirement among psychiatric medical staff so no or minimal additional costs 
were incurred at that stage.  With the stipulation that both costs of metabolic syndrome and 
services rendered by staff are underestimated, it is highly likely that there would still be a net 
gain per patient per year.  The ultimate benefit would be improved patient outcomes and 
extended life span, which cannot often be projected in dollars. 
Limitations  
Multiple barriers developed over the course of this project that may have impacted the final 
results in both under-estimating and over-estimating its effects.  Lengths of stay ranged from 2 to 
50 days with a mode of 4 days.  Shorter lengths of stay may prompt greater focus on the primary 
psychiatric concern regardless of other existing comorbidities, which essentially is the nature of 
this project’s concern.  Utilizing paper screens was an unavoidable barrier that led to a couple 
issues such as a significant data loss resulting in a sample size less than expected and 
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inconsistent completion by the user resulting in many incomplete individual screens.  
Implementation through an electronic medical record would improve generalizability and more 
comprehensive screening.  Another limitation of the screen was the ability to perform waist 
circumference measurements.  The very nature of the rationale for admission for this population 
is primarily psychiatric distress, which often precludes the ability for staff to take waist 
circumference measurements without risking their own safety.  Within the first three weeks of 
intervention, instructions were modified to allow for initial “eye-balling” waist circumference as 
either positive or negative criteria with the stipulation that the measurement be done at a later 
time.  This risk criteria indication was greatly diminished due to the lack of follow-up with only 
a 38% completion, however, body mass index was later used to assess that criteria with some 
accuracy.  The nature of the provider model at this facility also lent itself to challenges in that the 
providers rotated every several weeks, requiring frequent education throughout the process.  
Unfortunately, all providers have individual schedules so rotations ended and began at varying 
times so education was often provided too late in the process or not at all.  Another daunting 
challenge was that of consistent communication between nursing staff and provider staff.  There 
was no consistent way to ensure information of positive screens was followed up in a timely 
manner by the physicians and given the length-of-stay mode was 4 days, many possible 
interventions indicated may have fallen by the wayside in light of impending discharge. 
Conclusions. There are a multitude of factors impacting quality and longevity of life 
among individuals with severe mental illness.  One major factor is not only the presence of 
metabolic syndrome but the lack of screening for its presence and appropriate treatments in situ.  
A simple screening tool embedded into the existing electronic medical record could consistently 
identify patients at high risk for metabolic syndrome and focus attention on additional treatment 
METABOLIC SYNDROME SCREENING  18 
goals thereby improving delivery of those treatments.  Potential next steps would be to design an 
automatic triggering system within the electronic medical record to notify providers directly of 
positive screening criteria and allow for repeated reminders to address positive criteria until 
follow-up was documented.  This has the potential to mitigate barriers in screening efficacy and 
communication barriers between nursing staff originally assigned the screening role and the 
provider staff awaiting information to implement indicated treatments.  Further study in long 
term effects of enhanced evaluation and treatment of psychiatric patients with risk for metabolic 
syndrome would be valuable for future implementations of goal setting.  Quality provision of 
care is strongly enhanced with core measure requirements in the medical setting thus further 
study may be able to contribute to applications of core measure requirements in the psychiatric 
setting for improved patient outcomes for this disadvantaged population. 
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Appendix 
 
                                                                                                       DATE: __________________ 
1. National Institute of Health. (2016, June 22). National Heart, Lung, and Blood Institute Health Topics. Retrieved from 
How Is Metabolic Syndrome Diagnosed?: https://www.nhlbi.nih.gov/health/health-topics/topics/ms/diagnosis 
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Patient Sticker 
 
Metabolic Syndrome1 considered positive for MetS if 3 or more risk criteria present 
Measure Risk Criteria Positive Criteria 
Waist circumference Men > 40 inches; Women > 35 inches  
Triglycerides t 150 mg/dL  
HDL Cholesterol Men < 40 mg/dL; Women < 50 mg/dL  
Blood Pressure t 130 / t85 mmHg  
Fasting Blood Glucose t 100 mg/dL  
 
Waist circumference: 
• Waist measurement is at the level of the umbilicus 
• If patient is uncooperative, visual assessment is acceptable but must be re-
attempted when patient is cooperative 
Triglycerides/HDL: Request a new order or an add-on lab if available 
Blood Pressure: Per protocol; two consecutive readings for confirmation 
Fasting Blood Glucose: Request a one-time order or an add-on lab if available 
 
Does the patient meet 3 or more risk criteria for MetS?   
 Yes    No                 
Does the patient have a history/current use of antipsychotic medications?           
 Yes    No       
          
Does the patient have a current diagnosis of the following?   
 Hypertension         
          
 Hyperlipidemia        
          
 Diabetes          
          
Is the patient currently on any of the treatment below?   
 Antihypertensive                  
 Statin                    
 Insulin/oral antihyperglycemics      
          
If ANY box has been checked, has the physician been notified?   
 Yes    No       
 Physician name _____________________________________  
 
